Ventive Hospital (VENTIVE)

FairStock Score: 70/100 — STEADY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me assess Ventive the way Graham taught: buy with a margin of safety, and treat growth as a bonus, not as the price. Here, the market has already paid for extraordinary growth: price-to-earnings of 49.81 and EV/EBITDA of 169.51. The sales jump of 286.11% and profit jump of 426.58% are eye-catching, and the latest quarter of ₹686 Cr sales and ₹141 Cr net profit shows momentum. The Piotroski F-score of 8/9 also suggests the reported fundamentals are improving. But a value investor must ask: where is the cash? Free cash flow is minus ₹984 Cr, so the business is burning capital while reporting profit. Return on equity is only 6.74%; with debt/equity of 0.52, this is not a high-return franchise. In fact, with an Altman Z-score of 2.07, the balance sheet is in the grey zone. The Graham Number is ₹507.14, and at ₹621.25, I am buying with a negative margin of safety of about 37%. Promoter holding is 88.99%, which can be positive alignment, but in a company with such a small free float, prices can be distorted. Dividend yield of zero means I am relying solely on the story. There is no moat visible in these numbers; a hotel-resort classification for a hospital business only adds to the uncertainty. If this company can convert profits into free cash flow, improve ROE and de-lever, I would be interested. Today, Ventive is a fast grower, but as Graham said, the market is a voting machine in the short run and a weighing machine in the long run. Right now, the weighing machine shows negative cash flows and an expensive valuation. I'll pass.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer